Keurig
No proof required
Up to $50
13 days left
🔥 505 started this claim
J
Johnson & Johnson / Janssen Biotech
A $25 million settlement has been reached to resolve claims that Johnson & Johnson and Janssen Biotech suppressed generic Remicade competitors.
ClosedUnited States-wideClaim status: Closed on November 30, 2022Payout: VariesNo longer claimable
About this settlement
Allegations of suppressing generic Remicade (infliximab) competitors.
This settlement resolves claims that Johnson & Johnson and Janssen Biotech suppressed generic competitors for their drug Remicade. The settlement benefits individuals and entities who indirectly purchased, paid for, or were reimbursed for Remicade between April 5, 2016, and Feb. 28, 2022. Proof of purchase is required.
Who qualifies
- Individuals and entities who indirectly purchased, paid for, or were reimbursed for Remicade.
- Purchases made between April 5, 2016, and Feb. 28, 2022.
Varies
Claim status: Closed on November 30, 2022
Silk and Great Value
Proof required
Up to $300,000
113 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
763 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon
Keurig
No proof requiredNew
Up to $50
13 days left
Deadline July 8, 2026
🔥 505 started this claim
View settlement
Silk and Great Value
Proof requiredNew
Up to $300,000
113 days left
Deadline October 16, 2026
View settlement
Audible
No proof requiredNew
Compensation pending
Claims opening soon
Waiting for the claim window
View settlement
Government of Canada
Proof requiredNew
Up to $200,000
763 days left
Deadline July 27, 2028
View settlement